Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results

Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – February 7, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported…

Financial

Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical Programs and Corporate Highlights on Wednesday, February 7, 2018

Conference Call and Webcast To be Held Wednesday, February 7, 2018 at 4:30pm Eastern Time   NEW YORK, NY – February 5, 2017 – Anavex Life Sciences Corp., (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including Alzheimer’s disease, other central nervous…

Central Nervous System Noble

Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference

NEW YORK – January 24, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Rett syndrome, and other central nervous system (CNS) diseases, today announced that Christopher U. Missling, PhD, President and Chief Executive…

blood pressure , Anavex®2-73

Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical Hypertension

NEW YORK, NY – January 16, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases today reports that the peer-reviewed scientific journal The Journal of Clinical Hypertension [1] has published a post-hoc analysis of blood pressure data collected…

Anavex Life Sciences Financial results

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs

Anavex Life Sciences Reports Fiscal 2017 Financial Results And Provides Update On Therapeutic Programs Conference Call and Webcast Today at 4:30 p.m. ET NEW YORK – December 11, 2017 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases…

Anavex Life Sciences Reports Newly Published Data on Alzheimer’s Disease Research Demonstrate the Neuroprotective Features of the Sigma-1 Receptor

NEW YORK, NY – November 21, 2017 – New data published in the current issue of the peer-reviewed scientific journal Neurotoxicity Research[1] confirm that sigma-1 agonists, including multiple investigational compounds from Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL), induce an anti-oxidant effect and protect mitochondrial function in pathological central nervous system conditions. In…

Anavex Life Sciences to Present at the 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable in Washington, DC

NEW YORK – November 8, 2017 – Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and…